HOME >> BIOLOGY >> NEWS
The future of HIV therapeutics is brightening, according to Gladstone Institutes Director

Recent discoveries about the way that HIV infects cells are propelling the development of a broad spectrum of promising new antiviral drugs, according to an invited commentary on the topic in the current issue of Nature Immunology (August 27, 2004).

The assessment is made by Gladstone Institute of Virology and Immunology (GIVI) Director Warner Greene, MD, PhD, who also serves as professor of medicine, microbiology and immunology at the University of California, San Francisco.

In the piece, Greene points out that basic research on HIV, a relatively simple pathogen with only nine genes encoding 15 proteins, are leading to compelling new therapies that deny the initial entry of HIV into its cellular host. In addition, fast-moving research of naturally occurring factors with potent antiviral properties is opening the way for future development of an entirely new class of anti-HIV drugs.

New agents that block the first step in HIV's life cycle, the entry of the HIV virion (a single virus particle) into host CD4 T-cells, are quickly moving down the drug development pipeline. Chief among these therapeutics are drugs known as chemokine receptor antagonists that interfere with HIV's ability to bind to CCR5, one of two key surface receptors needed for the virus to penetrate the cell. Although these HIV co-receptors were identified only seven years ago, basic studies performed by both GIVI investigators and scientists around the world have helped accelerate clinical development of CCR5 antagonists as a new class of anti-HIV drugs. Several major pharmaceutical companies are now racing to the finishing line.

These advances address but one of the three steps required for successful entry of the HIV virus. The other two steps involve the attachment of HIV virions to surface CD4 receptors and the final fusion of virions to target cells. These steps are also being targeted with new antiviral drugs. Combinations of inhibitors acting at each o
'"/>

Contact: John Watson
jwatson@gladstone.ucsf.edu
415-695-3833
University of California - San Francisco
27-Aug-2004


Page: 1 2 3

Related biology news :

1. New fruitfly model of diabetes has future implications for pancreatic cell transplantation
2. Charting the future in prostate cancer care: A call to action
3. Sandia experiments may reduce possibility of future water wars
4. Will a reduction in military spending improve our environmental future?
5. Engineering endurance: The future of the Olympics?
6. The future of nanotechnology
7. Chemoradioimmunotherapy for advanced breast cancer: hope for the future?
8. Endometriosis: Could angiostatic therapy be the new treatment of the future?
9. Plants for the future: A European vision for plant biotechnology towards 2025
10. Plant pathologists to discuss the future of organic farming
11. Stem cells commit to a future of fat with one signal

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:11/13/2018)... ... 13, 2018 , ... Kenall has enhanced the popular MedMaster MAEC Series LED ... linear overbed luminaires are equipped with symmetric ambient and asymmetric exam modes, and an ... Intended to be specified in pairs, the MAEC is 8” x 48” and has ...
(Date:11/9/2018)... Pa. (PRWEB) , ... November 08, 2018 , ... ... with advanced touch screen control. Heating blocks, also known as dry bath incubators ... variety of tubes and containers. , For the new heating blocks, Boekel ...
(Date:11/7/2018)... ... 2018 , ... uBiome, the leader in microbial genomics, announces ... within the Department of Medicine, University of Colorado, Denver, to its Scientific Advisory ... Dr. Lozupone will bring to uBiome an expertise on the factors that shape ...
Breaking Biology News(10 mins):
(Date:11/5/2018)... ... November 05, 2018 , ... USARAD Holdings Inc., the leading ... several healthcare VC firms announces at Distributed Health 2018 conference November 5-6 (Nashville, ... tokens and obtaining its first radiology interpretations, one of the first known true ...
(Date:11/3/2018)... ... November 01, 2018 , ... Come to Princeton Nov. 14 ... Advisor, Division of Clinical Compliance Evaluation, CDER, FDA will be presenting on using ... What should clinical research industry stakeholders keep in mind when implementing and managing ...
(Date:10/31/2018)... ... October 30, 2018 , ... ... trial at the Campbell Clinic in Memphis, Tennessee. This study enrolled 125 ... standard of care for managing pain after total knee replacement surgery (TKA). , ...
(Date:10/31/2018)... ... October 30, 2018 , ... Today, the National Corn ... goal of this global competition is to find new and innovative uses of field ... corn farmers produced 14.6 billion bushels of corn and are on pace to produce ...
Breaking Biology Technology:
Cached News: